Terms: = Colorectal cancer AND TP63, EEC3, 8626, ENSG00000073282, p73H, p63, Q9H3D4, TP73L, p51, OFC8, KET, RHS, B p51B , B p51A , SHFM4, LMS, p73L AND Clinical Outcome
4 results:
1. colorectal adenosquamous carcinoma: Peculiar morphologic features and distinct immunoprofiles in squamous and glandular components.
Parente P; Mastracci L; Vanoli A; Businello G; Paudice M; Angerilli V; Castelvetere M; Graziano P; Fassan M; Grillo F
Pathol Res Pract; 2022 Aug; 236():153967. PubMed ID: 35662040
[TBL] [Abstract] [Full Text] [Related]
2. The prognostic significance of p63 cytoplasmic expression in colorectal cancer. An immunohistochemical study.
Albasri AM; Elkablawy MA; Ansari IA; Alhujaily AS; Khalil AA
Saudi Med J; 2019 May; 40(5):432-439. PubMed ID: 31056618
[TBL] [Abstract] [Full Text] [Related]
3. Histopathological variables in liver metastases of patients with stage IV colorectal cancer: potential prognostic relevance of poorly differentiated clusters.
Lionti S; Reggiani Bonetti L; Bettelli S; Spallanzani A; Gelsomino F; Barresi V
Hum Pathol; 2018 Aug; 78():115-124. PubMed ID: 29715463
[TBL] [Abstract] [Full Text] [Related]
4. Association of immune parameters with clinical outcome in stage III colon cancer: results of Southwest Oncology Group Protocol 9009.
Holcombe RF; Jacobson J; Dakhil SR; Stewart RM; Betzing KS; Kannan K; Macdonald JS
Cancer Immunol Immunother; 1999 Dec; 48(9):533-9. PubMed ID: 10602891
[TBL] [Abstract] [Full Text] [Related]
